Literature DB >> 27459003

Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A.

Seiji Tsunematsu1, Goki Suda1, Kazushi Yamasaki1, Megumi Kimura1, Takaaki Izumi1, Machiko Umemura1, Jun Ito1, Fumiyuki Sato1, Masato Nakai1, Takuya Sho1, Kenichi Morikawa1, Koji Ogawa1, Yasuhito Tanaka2, Koichi Watashi3, Takaji Wakita3, Naoya Sakamoto1.   

Abstract

Hepatitis B Virus (HBV) causes liver cirrhosis and hepatocellular carcinoma. Standard therapy includes treatment with interferon (IFN); however, its efficacy is limited. HBV has been reported to impair IFN signaling; however, the mechanism is unclear. Here, the relationship between HBV X protein (HBx) and IFN signaling was investigated by establishing HepG2 cells, stably expressing HBx (HepG2/HBx) via retrovirus-mediated gene transfer. Subsequently, IFN negative-regulator expression and its mechanism were studied. HepG2/HBx cells showed reduced expression of IFN-stimulated genes and expressed higher levels of suppressor of cytokine signaling 3 (SOCS3) and protein phosphatase 2A (PP2A) suppressor compared with control cells. Knockdown of SOCS3 and PP2A restored IFN sensitivity. Moreover, HepG2/HBx cells showed higher phosphorylation levels of signal transducers and activators of transcription 3 and endoplasmic reticulum stress, which are inducers of SOCS3 and PP2A, respectively. Additionally, HBx-knockdown restored IFN sensitivity in HepG2.2.15.7 cells. It was also confirmed that SOCS3 and PP2A expression levels were up-regulated in the liver of patients with HBV infection. The results of this study demonstrated that HBx impairs IFN signaling via increased expression of SOCS3 and PP2A, a novel mechanistic insight, providing a potential therapeutic target to enhance the efficiency of IFN therapy. J. Med. Virol. 89:267-275, 2017.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  biopsy; cytokine signaling 3; hepatitis B virus X protein; interferon signaling; protein phosphatase 2A

Mesh:

Substances:

Year:  2016        PMID: 27459003     DOI: 10.1002/jmv.24643

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  14 in total

Review 1.  The Dynamic Interface of Viruses with STATs.

Authors:  Angela R Harrison; Gregory W Moseley
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

Review 2.  Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment.

Authors:  Goki Suda; Koji Ogawa; Megumi Kimura; Masato Nakai; Takuya Sho; Kenichi Morikawa; Naoya Sakamoto
Journal:  J Clin Transl Hepatol       Date:  2016-12-26

Review 3.  Interplay between Janus Kinase/Signal Transducer and Activator of Transcription Signaling Activated by Type I Interferons and Viral Antagonism.

Authors:  Yuchen Nan; Chunyan Wu; Yan-Jin Zhang
Journal:  Front Immunol       Date:  2017-12-11       Impact factor: 7.561

Review 4.  Innate immune recognition and modulation in hepatitis D virus infection.

Authors:  Stephanie Jung; Sebastian Maximilian Altstetter; Ulrike Protzer
Journal:  World J Gastroenterol       Date:  2020-06-07       Impact factor: 5.742

5.  Construction of complete Tupaia belangeri transcriptome database by whole-genome and comprehensive RNA sequencing.

Authors:  Takahiro Sanada; Kyoko Tsukiyama-Kohara; Tadasu Shin-I; Naoki Yamamoto; Mohammad Enamul Hoque Kayesh; Daisuke Yamane; Jun-Ichiro Takano; Yumiko Shiogama; Yasuhiro Yasutomi; Kazuho Ikeo; Takashi Gojobori; Masashi Mizokami; Michinori Kohara
Journal:  Sci Rep       Date:  2019-08-26       Impact factor: 4.379

6.  PP2A Facilitates Porcine Reproductive and Respiratory Syndrome Virus Replication by Deactivating irf3 and Limiting Type I Interferon Production.

Authors:  Jiayu Xu; Lu Zhang; Yunfei Xu; He Zhang; Junxin Gao; Qian Wang; Zhijun Tian; Lv Xuan; Hongyan Chen; Yue Wang
Journal:  Viruses       Date:  2019-10-15       Impact factor: 5.048

7.  Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection.

Authors:  Kazuharu Suzuki; Goki Suda; Yoshiya Yamamoto; Ken Furuya; Masaru Baba; Akinobu Nakamura; Hideaki Miyoshi; Megumi Kimura; Osamu Maehara; Ren Yamada; Takashi Kitagataya; Koji Yamamoto; Taku Shigesawa; Akihisa Nakamura; Masatsugu Ohara; Naoki Kawagishi; Masato Nakai; Takuya Sho; Mitsuteru Natsuizaka; Kenichi Morikawa; Koji Ogawa; Shunsuke Ohnishi; Naoya Sakamoto
Journal:  J Gastroenterol       Date:  2020-11-19       Impact factor: 7.527

Review 8.  When Hepatitis B Virus Meets Interferons.

Authors:  Guangyun Tan; Hongxiao Song; Fengchao Xu; Genhong Cheng
Journal:  Front Microbiol       Date:  2018-07-18       Impact factor: 5.640

9.  Identification of potential key genes and pathways in hepatitis B virus-associated hepatocellular carcinoma by bioinformatics analyses.

Authors:  Xiang Zhang; Lingchen Wang; Yehong Yan
Journal:  Oncol Lett       Date:  2020-03-20       Impact factor: 2.967

10.  Type-I-IFN-Stimulated Gene TRIM5γ Inhibits HBV Replication by Promoting HBx Degradation.

Authors:  Guangyun Tan; Zhaohong Yi; Hongxiao Song; Fengchao Xu; Feng Li; Roghiyh Aliyari; Hong Zhang; Peishuang Du; Yanhua Ding; Junqi Niu; Xiaosong Wang; Lishan Su; F Xiao-Feng Qin; Genhong Cheng
Journal:  Cell Rep       Date:  2019-12-10       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.